Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Hydroxyurea is an excellent therapeutic agent for the pharmacological induction of HbF in patients with sickle cell disease (SCD). However, all completed clinical trials of hydroxyurea have excluded patients with hemoglobin SC (HbSC) disease. HbSC differs significantly in pathophysiology from HbSS, as HbC does not sickle, but instead causes cellular dehydration which potentiates sickling of HbS. Many severely affected HbSC patients have been placed on hydroxyurea on a case by case basis, but there are no large scale prospective data on safety or efficacy of hydroxyurea in this subset of patients with SCD. Here, we report a case series of 14 pediatric patients with HbSC treated to maximum tolerated dose (MTD) with hydroxyurea. Those who failed to show clinical improvement after at least six months at MTD were offered phlebotomy in addition to hydroxyurea. Five out of 11 patients with HbSC who achieved MTD failed to demonstrate clinical improvement on hydroxyurea. Of the four placed on dual hydroxyurea and phlebotomy therapy, all showed at least partial clinical improvement. Percent dense red blood cells (%DRBC) were measured via an ADVIA hematology analyzer. A marked rise in percent dense cells preceded clinical complications in three patients. Dual therapy with hydroxyurea and phlebotomy may be an effective approach to patients with HbSC that do not experience improvement with hydroxyurea alone. Monitoring of %DRBC may predict adverse events and aid in assessing hydroxyurea compliance. Large scale clinical trials are needed to evaluate the safety and efficacy of hydroxyurea and hydroxyurea with phlebotomy in patients with HbSC disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Fourteen children with HbSC disease, mean age 11 years, were given hydroxyurea at the maximum tolerated dose.HbF increased from 1.7 6 1.9% to 6.3 6 6.7%.75”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [75]
Citations
Cites
Blood Rheology and Hemodynamics
(2003) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2003-44551 · Cited by 1,006
Steinberg, M. H., Barton, F., Castro, O., Pegelow, C. H., Ballas, S. K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1645 · Cited by 931
How I use hydroxyurea to treat young patients with sickle cell anemia
Ware, R. E. (2010) · Blood · doi:10.1182/blood-2009-04-146852 · Cited by 396
Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?
Powars, D., Weiss, J., Chan, L., & Schroeder, W. (1984) · Blood · doi:10.1182/blood.v63.4.921.921 · Cited by 314
Zimmerman, S. A., Schultz, W. H., Davis, J. S., Pickens, C. V., Mortier, N. A., Howard, T. A., & Ware, R. E. (2004) · Blood · doi:10.1182/blood-2003-07-2475 · Cited by 313
The paradox of hemoglobin SC disease
Nagel, R. L., Fabry, M. E., & Steinberg, M. H. (2003) · Blood Reviews · doi:10.1016/s0268-960x(03)00003-1 · Cited by 271
The Role of Iron in Learning and Memory
Fretham, S. J. B., Carlson, E. S., & Georgieff, M. K. (2011) · Advances in Nutrition · doi:10.3945/an.110.000190 · Cited by 235
Frequency of Sickling Disorders in U.S. Blacks
Motulsky, A. G. (1973) · New England Journal of Medicine · doi:10.1056/nejm197301042880108 · Cited by 212
Hemoglobin sickle cell disease complications: a clinical study of 179 cases
Lionnet, F., Hammoudi, N., Stojanovic, K. S., Avellino, V., Grateau, G., Girot, R., & Haymann, J.-P. (2012) · Haematologica · doi:10.3324/haematol.2011.055202 · Cited by 172
Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo
Ballas, S. K., Dover, G. J., & Charache, S. (1989) · American Journal of Hematology · doi:10.1002/ajh.2830320206 · Cited by 157
Cited by
Fetal hemoglobin in sickle cell anemia
Steinberg, M. H. (2020) · Blood · doi:10.1182/blood.2020007645 · Cited by 136
Knowledge insufficient: the management of haemoglobin SC disease
Pecker, L. H., Schaefer, B. A., & Luchtman‐Jones, L. (2016) · British Journal of Haematology · doi:10.1111/bjh.14444 · Cited by 77
Clinical applications of therapeutic phlebotomy
Oh, K. Y., & Kim, K. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s108479 · Cited by 71
Genetic modifiers of severity in sickle cell disease
Chang, A. K., Summarell, C. C. G., Birdie, P. T., & Sheehan, V. (2018) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-189004 · Cited by 31
Self-citationTime to rethink haemoglobin threshold guidelines in sickle cell disease
Ballas, S. K., Kuypers, F. A., Gordeuk, V. R., Hankins, J. S., Thompson, A. A., & Vichinsky, E. P. (2021) · British Journal of Haematology · doi:10.1111/bjh.17578 · Cited by 18
Metadata
- Authors
- Summarell, C. C. G., & Sheehan, V. A.
- Affiliations
- Baylor College of Medicine (US)
- Corresponding author
- Sheehan, Vivien A
- ORCID
- Sheehan, Vivien A
- Venue
- Experimental Biology and Medicine
- Publisher
- Frontiers Media SA
- Published
- 2016-03-17
- Volume
- 241
- Issue
- 7
- Pages
- 737-744
- ISSN
- 0071-3384 (ISSN-L)
- 1535-3702
- 1535-3699
- PMC
- PMC4950384
- OpenAlex
- W2341094018
- Semantic Scholar
- 55bc6b4e01c91ab7b1d40d0189914be7962bf930
- Cited by
- 17
- References
- 26
- Citations by year
- 2026: 3 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 4 · 2018: 1 · 2016: 4
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Experimental Biology and Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K08DK110448)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Keywords
- hemoglobin SC disease, hydroxyurea, phlebotomy, sickle cell disease, fetal hemoglobin induction, pediatric patients, maximum tolerated dose, treatment failure, adverse event prediction
- MeSH terms
- Antisickling Agents, Child, Combined Modality Therapy, Female, Hemoglobin SC Disease, Humans, Hydroxyurea, Male, Phlebotomy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease. https://app.cochat.ai/papers/10.1177/1535370216639737
- The paper
- Summarell, C. C. G., & Sheehan, V. A. (2016). Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease. Experimental Biology and Medicine. https://doi.org/10.1177/1535370216639737
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.